PDCD1 and cancer: Our analysis indicates that cancers with a high TMB, such as melanoma and non–small cell lung cancer, are associated with a higher irAE ROR during anti–PD-1 therapy, strongly suggesting that these cancers are associated with a higher risk of irAEs than cancers with a low TMB.